Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2012 Nov;59(5):934-8

Date

06/01/2012

Pubmed ID

22648868

Pubmed Central ID

PMC3528889

DOI

10.1002/pbc.24103

Scopus ID

2-s2.0-84866169497   98 Citations

Abstract

Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.

Author List

Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, Recht M, Silverman RA, Tom WL, Pope E

Author

Yvonne E. Chiu MD Vice Chair, Professor in the Dermatology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adrenergic beta-Antagonists
Child, Preschool
Female
Hemangioendothelioma
Hemangioma
Humans
Infant
Infant, Newborn
Kasabach-Merritt Syndrome
Male
Propranolol
Sarcoma, Kaposi
Skin Neoplasms